You are here: Home / GW Innovations / Technologies Available

Optimization of Cold Atmospheric Plasma-Stimulated Media for Treatment of Cancer

Technology #016-011-keidar

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
3-Nitro-L-tyrosine inhibits the degradation of cold plasma-stimulated DMEM. The change of anti-cancer capacity of the cold plasma-stimulatedstandard DMEM and 3-Nitro-L-tyrosine-containing DMEM during the storage at 8 °C for 3 days.
Michael Keidar
External Link (
Dayun Yan
Jonathan Sherman
Managed By
Brian Coblitz
Sr. Licensing Associate (202) 994-4345
Patent Protection

Provisional Patent Application Filed
Stabilizing the cold plasma-stimulated medium by regulating medium’s composition
Scientific Reports, 2016 May 13;6:26016.

Previously, GW researchers invented a method to selectively kill cancer cells with cold atmospheric plasma (CAP) while leaving neighboring normal cells intact.  In a subsequent study, the researchers showed that similar anti-cancer effects can be achieved indirectly using CAP-stimulated media (CAPSM).

Stability of CAPSM (preservation of its anti-cancer property over time) is a key consideration for its future clinical application.  Previously, others have reported that CAPSM needs to be stored at -80ºC (-112ºF) for it to maintain its stability for 7 days.  In the current invention, GW researchers demonstrate that stability of CAPSM can be maintained for 3-7 days at 8ºC by using PBS or modified DMEM as the media.

In addition, the current invention identifies a number of stimulation parameters that can affect the anti-cancer capacity of CAPSM.  These parameters include (1) plasma treatment time, (2) well size, (3) size of the gap between the plasma source and the media, (4) volume of media, and (5) specific amino acid contents of the media.  This invention enables optimization of CAPSM therapy to have high anti-cancer capability.  Given that CAPSM may be useful in instances where direct application of CAP to tumor cells or tissues is not feasible, the current invention may lead to a broader application of CAP-based cancer treatments.

The original CAP therapy device has been used on a human patient under a therapeutic use exemption to treat the area where a tumor was surgically removed, in order to kill any tumor cells that may have been left behind and prevent remission. Submission for FDA approval of the CAP device is anticipated in 2016.


  • Cancer therapy


  • Applicable in situations where CAP treatment (direct exposure of tumors to CAP) is not feasible.
  • Plasma device can reside at manufacturing facility, instead of in operating room.
  • Enables sales of single use product versus expensive device.